February 27, 2020 / 12:14 PM / a month ago

BRIEF-India's Glenmark Pharma & UK's Hikma Enter Exclusive Licensing Agreement For Nasal Spray In U.S.

Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd:

* SAYS CO, HIKMA ENTER EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZING RYALTRIS™ SEASONAL ALLERGIC RHINITIS NASAL SPRAY IN US

* SAYS WILL RECEIVE AN UPFRONT PAYMENT, REGULATORY APPROVAL AND COMMERCIAL MILESTONE PAYMENTS. ROYALTIES FROM HIKMA

* GLENMARK WILL BE RESPONSIBLE FOR THE CONTINUED DEVELOPMENT AND REGULATORY APPROVAL OF RYALTRIS BY US FDA

* HIKMA TO BE RESPONSIBLE FOR COMMERCIALIZATION OF RYALTRIS IN U.S. FOLLOWING FDA APPROVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below